Vaxcyte, Inc. (PCVX) stock
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$64.69−3.93 (-5.73%)
Close on Nov 12, 2026Market cap $9.63BP/E –Yield 0.00%
Vaxcyte r&d expenses
Research and development expenses are spending on new products and technology.
Vaxcyte's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.09B, up 59.4% year over year. For fiscal 2025 it was $794.31M, up 66.6% from the year before. The highest annual figure on record is $794.31M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $794.31M | +66.6% |
| FY2024 | Dec 31, 2024 | $476.64M | +43.4% |
| FY2023 | Dec 31, 2023 | $332.34M | +96.1% |
| FY2022 | Dec 31, 2022 | $169.45M | +116.1% |
| FY2021 | Dec 31, 2021 | $78.41M | +6.6% |
| FY2020 | Dec 31, 2020 | $73.56M | +61.3% |
| FY2019 | Dec 31, 2019 | $45.61M | +51.3% |
| FY2018 | Dec 31, 2018 | $30.15M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $270.33M | +28.8% |
| Q2 FY2026 | Jun 30, 2026 | $267.85M | +37.9% |
| Q1 FY2026 | Mar 31, 2026 | $312.78M | +111.1% |
| Q4 FY2025 | Dec 31, 2025 | $242.06M | +81.2% |
| Q3 FY2025 | Sep 30, 2025 | $209.93M | +79.5% |
| Q2 FY2025 | Jun 30, 2025 | $194.18M | +47.7% |
| Q1 FY2025 | Mar 31, 2025 | $148.13M | +56.6% |
| Q4 FY2024 | Dec 31, 2024 | $133.61M | +28.3% |
| Q3 FY2024 | Sep 30, 2024 | $116.94M | +20.0% |
| Q2 FY2024 | Jun 30, 2024 | $131.51M | +80.9% |
| Q1 FY2024 | Mar 31, 2024 | $94.59M | +62.9% |
| Q4 FY2023 | Dec 31, 2023 | $104.15M | +101.7% |
| Q3 FY2023 | Sep 30, 2023 | $97.42M | +104.3% |
| Q2 FY2023 | Jun 30, 2023 | $72.69M | +89.0% |
| Q1 FY2023 | Mar 31, 2023 | $58.08M | +83.3% |
| Q4 FY2022 | Dec 31, 2022 | $51.63M | +123.7% |
| Q3 FY2022 | Sep 30, 2022 | $47.68M | +133.4% |
| Q2 FY2022 | Jun 30, 2022 | $38.47M | +117.9% |
| Q1 FY2022 | Mar 31, 2022 | $31.68M | +83.6% |
| Q4 FY2021 | Dec 31, 2021 | $23.07M | +57.4% |
| Q3 FY2021 | Sep 30, 2021 | $20.43M | +24.5% |
| Q2 FY2021 | Jun 30, 2021 | $17.65M | -2.9% |
| Q1 FY2021 | Mar 31, 2021 | $17.26M | -29.0% |
| Q4 FY2020 | Dec 31, 2020 | $14.66M | +9.6% |
| Q3 FY2020 | Sep 30, 2020 | $16.41M | +70.4% |
| Q2 FY2020 | Jun 30, 2020 | $18.18M | +82.4% |
| Q1 FY2020 | Mar 31, 2020 | $24.32M | +92.5% |
| Q4 FY2019 | Dec 31, 2019 | $13.38M | – |
| Q3 FY2019 | Sep 30, 2019 | $9.63M | – |
| Q2 FY2019 | Jun 30, 2019 | $9.97M | – |
| Q1 FY2019 | Mar 31, 2019 | $12.63M | – |
See a number that looks wrong?